Predicting bone relapse of breast cancer using markers

摘要

Disclosed is a method of assessing breast cancer status comprising the step of measuring the expression levels of genes in a biological sample obtained from a breast cancer patient via a Marker, wherein "Marker" means a) genes and gene expression products such as RNA, mRNA and corresponding cDNA, peptides, proteins, fragments and complements of each of the foregoing, and b) compositions such as probes, antibodies, ligands, haptens, and labels that, through physical or chemical interaction with a) indicate the expression of the gene or presence of the gene expression product and wherein the gene, gene expression product or compositions correspond with: i) SEQ ID NO 112, ii) a combination of SEQ ID NO 112 and a member of the group consisting of SEQ ID NO 113, SEQ ID NO 114, SEQ ID NO 115, SEQ ID NO 116, iii) a combination of SEQ ID NO 112 and all of SEQ ID NO 113, SEQ ID NO 114, SEQ ID NO 115, and SEQ ID NO 116, iv) SEQ ID NO 112 and one or more of SEQ ID NO 116-198, or v) all of SEQ ID NO 112- SEQ ID NO 198, wherein the gene expression levels above or below pre-determined cut-off levels are indicative of the likelihood of relapse in bone, wherein the pre-determined cut-off levels are at least 1.7-fold over- or under-expression in the sample relative to cells or tissue from non-bone relapsing patients. Also disclosed are kits and microarrays for performing the method.